Summary Antioxidant therapy has a potential to be introduced as therapeutic modality for chronic obstructive pulmonary disease (COPD) patients. This study aimed to determine the effect of antioxidant supplementation [ascorbic acid and N-Acetylcysteine (NAC)] on nutritional and antioxidant status in male COPD patients. A parallel and single blind randomised controlled clinical trial (RCT) was conducted at two medical centers in Kuala Lumpur, Malaysia. Seventy-nine subjects were recruited and randomly divided into four trial arms (i.e., NAC, vitamin C, NACϩvitamin C and control groups) for six mo. The primary outcome was changes in body mass index by estimating power of 90% and signifi cance level of pϽ0.05. Repeated Measure ANOVA showed that there was a signifi cant interaction effect on BMI (pϭ0.046) and carbohydrate intake (pϭ0.030), especially in the NAC group. Plasma glutathione (GSH) increased signifi cantly in all intervention groups, especially in vitamin C (pϭ0.005). A single supplementation of NAC or vitamin C improved nutritional and antioxidant status of subjects.
estimated that 64 million people had COPD and 3 million people died from COPD in 2005, accounting for 5% of all deaths globally with almost 90% of the deaths coming from countries of low to middle income (1) . The prevalence of COPD in Asia, Europe or North America ranged between 4% and 10% (2) . The prevalence in Malaysia estimated using an estimation model was 4.7% (3) . Epidemiological studies suggested that dietary habits may infl uence the occurrence of common lung diseases such as asthma, COPD and lung cancer (4) . In particular, COPD not only affects the lungs, but also produces signifi cant systemic consequences such as weight loss and muscle dysfunction (5) . Thus, malnutrition is a common problem in patients with COPD. The prevalence of malnutrition among COPD patients ranges from 20 to 50%, depending on disease severity (6) .
Defi ciency in antioxidants may contribute to oxidative stress leading to the development of airfl ow limitation. Hence, dietary supplementation may be a benefi cial therapeutic intervention in this condition (7) . A systematic review on the effect of an antioxidant supplementation, namely NAC among COPD patients, revealed that 48.5% of patients receiving NAC had no exacerbations, compared to 31.2% among the placebo group (8) . Five out of nine studies reported that NAC supplementation improved symptoms of 61.4% of the treated patients compared to 34.6% in placebo group. However, none of the studies evaluated the effect of NAC supplementation on the nutritional or antioxidant status. Although vitamin C has been reported to improve the antioxidant status among smokers (9) , little is known about the efficacy of vitamin C on COPD patients. Data from a representative sample of adults in the USA (NHANES II), showed an inverse relationship between both dietary and serum vitamin C and chronic respiratory symptoms (10) and function as measured using FEV1 (11) . It was suggested that higher dietary intake and serum concentrations of vitamin C had a protective effect against respiratory symptoms and lung function (12) . Fruit and fi sh consumption may partly explain population differences in COPD mortality (13) . Further, fruit and whole grain intake showed independent benefi cial associations with COPD (14) . Therefore, this study aimed to evaluate the effi cacy of ascorbic acid and NAC supplementation either alone or in combination on the nutritional and antioxidant status among male COPD patients.
MATERIALS AND METHODS
Study design and subjects. A single blind RCT was conducted among male COPD subjects, at the outpa- (15) by the physician, with forced expiratory volume in the fi rst second (FEV1) Ͻ80% predicted and FEV1/FVC Ͻ70% using Spirobank G. Patients who regularly took antioxidant supplementation or had been hospitalised for the past three months, or diagnosed with COPD at stage IV, malignancy, or co-morbidities such as diabetes mellitus (DM), tuberculosis (TB), and infl ammatory disease were excluded.
Subjects were randomly assigned to four groups, i.e., N-acetylcysteine (NAC) 600 mg (NAC), vitamin C 500 mg (Vitamin C), a combination of vitamin C (500 mg) and NAC (600 mg) (NACϩVitamin C) once daily and a control group (Fig. 1) . Simple randomization was used with four folded cards (representing each arm of the trial) that were prepared to be picked up by each subject upon recruitment. The primary outcome, i.e., nutritional status, and secondary outcomes, i.e., antioxidant status, of subjects were measured at baseline, and 3 and 6 mo of intervention. Measurements. Nutritional status was determined using anthropometric indicators including weight, height, mid upper arm circumference (MUAC), triceps skin fold thickness (TSFT) waist circumference (WC) (16, 17) , calf circumference (CC) (18) , and hip circumference (HC) (19) ; using standard method (17, 18) . Dietary intake was also obtained and analysed using Nutritionist-Pro software. Appetite was measured using the Council on Nutrition Appetite Questionnaire (CNAQ) (20) . Body composition [fat free mass (FFM), fat mass (FM)] was also measured using a bio impedance analysis (BIA) technique (Maltron, B-F 900, England). Subjects were instructed not to exercise or take a sauna within 12 h and to refrain from alcohol intake, coffee, tea, and fi zzy or energy drinks for at least 24 h prior to the procedure. Subjects were also asked to urinate 30 min before, and to avoid food or drink two to three hours before the test.
Biochemical analysis. A total of 10 mL fasting venous blood was drawn for measurement of antioxidant status (vitamin A, vitamin E, vitamin C, glutathione and total antioxidant capacity). Vitamin C (L-ascorbic acid, purity 99%), Vitamin E (Ϯ␣-tocopherol, purity 95%) and vitamin A (␤-carotene, purity 97%) were obtained from Sigma Chemical Company (St. Louis, MO). The methanol, acetonitrile and tetrahydrofuran were obtained from Merck KGaA (Darmstadt, Germany). Vitamin A (retinol) and E (␣-tocopherol) in serum/plasma were measured using isocratic high performance liquid chromatography (HPLC) with detection at three different wavelengths (21) . Vitamin C was determined and about 0.5 mL plasma was mixed with the oxalic acid preservative and wrapped with aluminum foil to keep at Ϫ70˚C until analysis using HPLC (22) (Waters 2998 Separation Module), with the mobile phase at a fl ow rate of 1.2 mL/min and a column [LiChrospher 100 RP-18 column, (125ϫ4 mm I.D.; particle size, 5 m)] from Merck KGaA. Total antioxidant capacity was measured by the ferric reducing antioxidant power (FRAP) assay (23) . The Calbiochem ® GSH Assay Kit II (Cat. No. 354103) was used to determine the concentration of GSH in human plasma. The antioxidant factors in blood such as albumin, bilirubin and uric acid had not been measured as the main antioxidants. The concentrations of these non-enzymatic antioxidants are low in the epithelial lining fl uid (ELF) in the lungs (24, 25) .
Sample size calculation and statistical analysis. The sample size was calculated using the following formula. The standard deviation for nutritional status, i.e., BMI based on previous study, was 6.1 among COPD patients in Malaysia (26) . Therefore, the difference to be detected was dϭ7 with considering 30% for attrition. Thus, 80 subjects were required to be randomly divided into four trials.
Data was analysed using the statistical package for social sciences (SPSS) version 16. One-Way ANOVA and the Kruskal-Wallis Test were used to determine any differences between groups, for parametric and non-parametric tests, respectively. The effect of supplementation was assessed using Two-Way Mixed ANOVA. Analysis was carried out at the pϽ0.05 signifi cance level by estimating power of 90%, using changes in Body Mass Index (BMI) followed by an antioxidant therapy (26) as the primary outcome.
RESULTS

Subjects
Seventy-nine eligible subjects (mean age 64.04Ϯ 8.32 y, 43-76 y old) participated, with a 22.8% dropout mostly occurring within the fi rst months of the trial; therefore, the intention to treat analysis has not been performed (nϭ61) (Fig. 1) . The compliance was checked monthly either upon the scheduled appointment or using phone calls. Among the complaints were polyuria, numbness and stiffness (nϭ1 from vitamin C group, nϭ1 from NAC group), dyspnea and numbness (nϭ1, NAC group) and facial fl ushing (nϭ1, NACϩvi-tamin C). Only one dropout occurred in the NACϩvita-min C group due to the specifi c side effect of the supplements. Other dropouts occurred mainly due to lack of interest in continuing the study (nϭ7), and diffi culty in keeping the scheduled monthly appointment (nϭ2). At baseline, the intervention and control groups were comparable with respect to age, income, number of cigarettes smoked (packs per year), smoking index, and COPD duration, as shown in Table 1 . They were also comparable with respect to anthropometry, food intake and antioxidant status.
Effect of supplementation on nutritional status
Repeated Measures ANOVA analysis showed that the mean BMI increased signifi cantly, especially in the NAC group when compared with the other interventions (pϭ0.046) ( Table 2 ). The percentage of change in BMI was the highest in the NAC group (1.23%), followed by vitamin C (0.4%), control (Ϫ0.09%) and NACϩvita-min C groups (Ϫ2.8%) (Fig. 2 ). There was a signifi cant time effect change in body composition, i.e., body fat mass (pϽ0.001), muscle mass and FFMI and also CNAQ score. FFMI signifi cantly decreased over time in the NAC, vitamin C and control groups, but increased in the NACϩvitamin C group after 3 mo and then decreased after 6 mo. The mean score for CNAQ was signifi cantly increased over time in all the trial groups (pϽ0.001), as compared to the control group ( Table 2 ). The percentage of carbohydrate intake signifi cantly increased due to the intervention (Table 3 ). The percentage of change in carbohydrate intake was the highest in the NACϩvitamin C group (11.9%), followed by the NAC (7.4%), control (4.5%) and vitamin C groups (Ϫ9.6%). There was also a signifi cant time effect on the percentage of fat intake, vitamin A intake and ␤-carotene intake ( Table 3) .
Effect of supplementation on antioxidant status
The mean plasma GSH rose in all the intervention groups as compared to the control group (Table 4 ). The percentage increase was the highest in the vitamin C group (516%), followed by the NAC (171%), NACϩvita-min C (103%) and control groups (56%) (Fig. 3) . There was signifi cant change for plasma vitamin A (pϭ0.001) over time ( Table 4 ). The percentage of increment was the highest in the vitamin C group (499%) followed by the NAC (413%), NACϩvitamin C (408%) and control groups (75%).
DISCUSSION
The trial has successfully evaluated the effect of six mo' antioxidant supplementation on the nutritional and antioxidant status of COPD patients.
Antioxidant supplementation led to an improvement in appetite score in all trial groups, compared to the control. A similar fi nding was observed in an earlier study, in which appetite improved after eight weeks on a pulmonary rehabilitation programme (26) . Another study found that the intake of energy, protein and carbohydrate increased after attending nutritional counseling sessions (27) . In addition to appetite, the present study showed an improvement in carbohydrate intake following antioxidant supplementation. Another study also found that supplementation of lipoic acid and NAC was a useful treatment for cancer or HIV-induced weight loss (28) . The oxidative stress is an important feature in the pathogenesis of COPD and poor respiratory function. This leads to a sedentary life style due to gas exchange (29, 30) , resulting in loss of appetite which leads to nutrient defi ciency through consumption of a low-antioxidant diet. Antioxidant supplementation including NAC scavenged free radicals, thus reducing oxidative stress and cytokines, leading to improvement in appetite. As shown in cancer patients, chronic infl ammation could trigger the overproduction of proinfl ammatory cytokines, playing a major role in the pathogenesis of systemic symptoms in cachexia patients (31, 32) .
In COPD patients, of whom chronic infl ammation is a major characteristic, a similar mechanism may occur. NAC supplementation showed an improvement in nutritional status (BMI). This fi nding was in agreement with an earlier report in which oral glutathione supplementation among COPD patients increased nutritional parameters (33) .
Although there is a lack of data regarding vitamin C supplementation among COPD patients, the present study revealed that vitamin C supplementation has the potential to improve lung function. The non-enzymatic antioxidants in the lungs include low molecular weight compounds such as glutathione (GSH), ascorbate, urate, bilirubin, lipoic acid and alpha-tocopherol. Concentrations of these non-enzymatic antioxidants vary in the lungs. Glutathione and vitamin C are more concentrated in ELF compared to plasma as their specifi c effects in the lungs (34, 25) and others, such as albumin and bilirubin, are found in high concentration in serum, but at much lower concentrations in the ELF (24, 25) . Vitamin C has a major function in addition to its role as an enzyme cofactor, it being a key chain-breaking antioxidant in the aqueous phase (35) . Vitamin C, in the presence of increased free radical production, can be rapidly deleted by electron spin resonance in body fl uids (36) as observed in this study; in the presence of increased lipid peroxidation, the concentration of vitamin C did not increase in the vitamin C or NACϩvitamin C group. The mechanism of the antioxidant defense systems in the lung and their overlapping specifi c activities suggested normal pulmonary cellular function needs adequate redox balance (37) .
Antioxidant status (glutathione) increased after 6 mo' supplementation in all intervention groups, especially in the vitamin C group. Oral supplementation with NAC as a precursor of GSH boosts the intracellular glutathione via elevated intracellular cysteine (38) . In this process, in the presence of a high GSH concentration, GSH is converted to its oxidized form, glutathione disulfi de (GSSG), as a free radical (39) . Therefore, in the NAC group there was a signifi cant presence of GSH free radicals (GSSG); hence the increment of GSH was not high as we expected. Vitamin C can regenerate a GSH radical to its antioxidant. Hence, the highest increment of GSH was observed in the vitamin C group. Vitamin C creates a chain of antioxidant molecule dependency (38) . Therefore, supplementation of vitamin C may lead to an increase in GSH without changing its level in the plasma, as was observed in the current study. As a limitation, the initial plasma GSH was randomly low in the control group as compared to other intervention groups. In the statistical results each intervention group was compared with the baseline, month 3 and month 6 of its group. The main limitation of the study was the small sample size. A multicenter trial should be conducted to increase the sample size, taking into consideration respiratory function as the primary outcome. A double blind control placebo controlled study should be conducted to obtain an unbiased result. The trial was not registered in an open access data base prior to the study due to lack of funding.
Conclusion
Antioxidant supplementation, particularly NAC, was able to improve nutritional status. Vitamin C was effective in improving antioxidant status. However, a longer period of supplementation should be monitored. In the future researchers may build on these results and establish COPD/respiratory-related fi ndings such as longer study duration, monitoring pulmonary function decline over time and the use of substitute antioxidant agents.
